Grifols receives FDA approval for donor screening assay.
Grifols, a producer of plasma-derived medicines and a developer of diagnostic solutions, announced that the FDA approved the Procleix Babesia assay, a qualitative assay for the detection of the ribosomal RNA from four Babesia species (B. microti, B. duncani, B. divergens, B. venatorum) in individual samples or up to 16 pooled lysed specimens from human donors, including donors of whole blood and blood components for transfusion.
The assay runs on the Procleix Panther system--a fully automated platform utilizing Nucleic Acid Testing (NAT) for blood screening. The FDA approval recognizes a successful multi-center clinical trial conducted under an Investigational New Drug (IND) study at the American Red Cross, Creative Testing Solutions, and Rhode Island Blood Center (an affiliate of the New York Blood Center, Inc.), in select areas of the U.S.
Babesia is a parasite that can be transmitted to humans by tick bites or through donated blood from Babesia-infected donors.
According to the Centers for Disease Control and Prevention (CDC), the highest numbers of Babesia infections occurred in Massachusetts, New York, Connecticut, Rhode Island, New Jersey, Maine, New Hampshire, Wisconsin, and Minnesota.
|Printer friendly Cite/link Email Feedback|
|Publication:||Medical Laboratory Observer|
|Date:||Apr 1, 2019|
|Previous Article:||Older biologic age linked to elevated breast cancer risk.|
|Next Article:||Incidents of vocal cord cancer are on the rise in children, teens and young adults under 30.|